EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank43
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P43
Within normal range
vs 5Y Ago
-1.2x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-90.22%
2024-6832.05%
2023102.88%
2022-29.76%
2021-247.05%
202074.54%
2019-158.82%
2018-6.92%
2017-25.58%
2016-258.45%